Year: 2022

news_6

BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tislelizumab in First-Line RM-NPC in Virtual ASCO Plenary Series

Progression-Free Survival Benefit of Tislelizumab in Combination with Chemotherapy Sustained at Median 15.5 Month Follow-up Secondary Survival Endpoint Findings Were...

generic_link-66

Bartra Wealth Advisors Releases Survey Findings: Nearly 80 Percent of Respondents Have an Intention to Emigrate, Ireland Ranks in Top Three Most Popular Hong Kong Emigration Destinations